Rajasthan Antibiotics Ltd to Raise Rs. 50 Crore VC Funding

Tuesday, May 9, 2017 Drug News
Email Print This Page Comment
Font : A-A+

Rajasthan Antibiotics Limited (RAL), leading pharmaceutical company, is planning to raise an amount of Rs. 50 crores through venture capital (VC) funding by August-September 2017. BIORx Venture Advisors Pvt Limited (BIORx) has been mandated to syndicate funds. The funding would be pumped into company expansion through Greenfield and Brownfield. BIORx works as a financial and strategic partner for the life-sciences industry.

In the past 25 years, RAL has grown both in size and reputation to become the nation’s largest producer of injectable antibiotics. Mr. Ashish Pruthi, MD, RAL, said, “Our next target is to generate a revenue of INR 500 crores by 2020 and strengthening our position in the ever-growing niche segment of Steriles.”

About Rajasthan Antibiotics Ltd (RAL)

RAL, one of the fastest growing pharmaceutical companies in North India and having its corporate office based out of Delhi are always on the move to develop innovative products at very competitive prices. It is also very efficiently harnessing its funds for improving manufacturing facilities and upgrading the existing R&D department. The company has got a great clientele base not only in India but also in Europe and countries like China, Brazil, Indonesia, Bangladesh and UAE where it has already made its presence felt.

RAL was incorporated on March 17, 1986, and commenced commercial production in the year 1991. RAL is engaged in the manufacturing of bulk drugs, also known as active pharmaceutical ingredients (API's). The company has a diversified product mix that largely caters to two therapeutic segments, namely, Anti-Infective and gastroenterology.

RAL has a well established and diversified customer base across domestic as well as export markets. The company has the following key features:

  • Long experience of promoters in the pharmaceutical industry.
  • Accredited manufacturing facilities.
  • Diversified Product profile.
  • Low client concentration risk.
  • Stable industry prospects.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook